+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 333 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating the effectiveness and safety of elenestinib BLU-263 combined with symptom directed therapy SDT compared to placebo plus SDT in adults with indolent systemic mastocytosis ISM whose symptoms are not well controlled by SDT alone. This Phase 23 randomized, double-blind, placebo-controlled study includes participants from Parts 1 and 2 with ISM, with those in Part 2 continuing into Part 3 for open-label elenestinib treatment. Part K enrolls participants with prior use of selective KIT inhibitors, and additional pharmacokinetic groups will also participate. Participants receive SDT tailored individually and take either oral elenestinib or matching placebo once daily. In Part 1, treatment continues until study completion, while Part 2 involves approximately 48 weeks of dosing. Part 3 and other parts may extend treatment up to about 5 years. The study monitors participants throughout these periods, with dosing and symptom management adjusted as needed. During the study, participants undergo various assessments including symptom scoring with the Indolent Systemic Mastocytosis-Symptom Assessment Form ISM-SAF, safety monitoring for adverse events, and laboratory tests such as serum tryptase levels and KIT D816V allele fraction. Bone marrow mast cells, bone mineral density, and quality of life measures are also evaluated. Researchers track these outcomes at multiple timepoints from baseline up to 5 years to understand treatment impact and participant safety.

Age: 18Years +All GendersPhase 2Phase 3
88 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating MammoWave, a device that uses low-power microwaves instead of X-rays, for early breast cancer detection in women aged 45 to 74. This prospective, multicenter clinical investigation aims to confirm that MammoWave achieves sensitivity greater than 75% and specificity greater than 90% for breast cancer detection among 10,000 volunteers undergoing regular screening programs. The study compares MammoWave results with conventional breast examination methods including mammograms and other radiological or histological tests. Participants will undergo both the standard breast screening exams and the MammoWave exam. The MammoWave exam involves lying prone on a bed while the device collects microwave data from both breasts over about 8 minutes. Data processing uses a special imaging algorithm to produce microwave images and classification results indicating suspicious or non-suspicious findings. The study device contains the same hardware as a CE-marked version but uses updated software. During the study, participants will have conventional breast exams along with the MammoWave exam. Researchers will evaluate MammoWaves sensitivity and specificity during the procedure and analyze detection rates, recall rates, and positive predictive values at baseline. Volunteers will also complete satisfaction questionnaires. The study will monitor breast cancer detection by histological type, size, and breast density. The trial is expected to run until December 2026.

Age: 45Years - 74YearsFEMALEPhase Not Applicable
10 locations
S

Actively Recruiting

This research aims to find out if intismeran autogene combined with pembrolizumab can stop the growth or spread of advanced melanoma, a type of skin cancer that has spread to other parts of the body and cannot be removed by surgery. The study compares this combination to a placebo with pembrolizumab to see if people live longer without their cancer worsening. Immunotherapy, which helps the immune system fight cancer, is the standard treatment for advanced melanoma. Participants in the study will be randomly assigned to receive either intismeran autogene by intramuscular injection every three weeks for up to nine doses plus pembrolizumab by intravenous infusion every six weeks for up to 17 doses or until the disease progresses or they stop treatment. Alternatively, they will receive a placebo injection on the same schedule plus pembrolizumab. The total treatment duration can last up to about two years. During the study, participants will be monitored for cancer progression and survival for up to about three years for progression-free survival and up to six years for other outcomes including overall response and survival. Researchers will collect tumor tissue samples for genetic and biomarker analyses and assess safety by tracking adverse events and treatment discontinuations. The study involves regular visits for treatments and assessments throughout the treatment period and follow-up monitoring.

Age: 18Years +All GendersPhase 2
38 locations
S

Actively Recruiting

Researchers are investigating new treatments for high-risk, early-stage breast cancer, focusing on triple-negative breast cancer TNBC and hormone receptor-low positiveHER2-negative breast cancer. These types are defined by low or absent HER2 protein and hormone receptors. The study aims to evaluate whether adding sacituzumab tirumotecan sac-TMT, a targeted therapy, to pembrolizumab and chemotherapy improves outcomes compared to pembrolizumab plus chemotherapy alone. Participants are randomly assigned to one of two groups. One group receives sac-TMT intravenously every two weeks with pembrolizumab every three weeks for 12 weeks, followed by pembrolizumab combined with carboplatin and paclitaxel for another 12 weeks, surgery, optional radiation, and additional pembrolizumab for up to 28 weeks. The other group receives carboplatin and paclitaxel with pembrolizumab for 6 weeks, followed by pembrolizumab combined with cyclophosphamide and either doxorubicin or epirubicin for up to 12 weeks, surgery, optional radiation, and pembrolizumab for up to 28 weeks. Additional adjuvant treatments may be given to participants with residual disease. During the study, participants undergo assessments including tumor biopsies, surgery, and optional radiation therapy. Researchers monitor outcomes such as the percentage of participants with no detectable cancer at surgery and event-free survival over up to 92 months. Secondary measures include overall survival, quality of life, side effects, and adverse events. The total study duration may extend up to nearly 10 years to monitor long-term effects and safety.

Age: 18Years +All GendersPhase 3
331 locations
T

Actively Recruiting

Healthy Volunteer

Researchers are evaluating CPV-104, a new medicine designed to regulate the complement system, which may be overactive in C3 glomerulopathy C3G, an ultra-rare kidney disorder. This phase 1 trial is the first time CPV-104 is tested in humans, including both healthy adults and adults with C3G. The study aims to assess safety, tolerability, how the body processes the medicine, and immune system reactions. The trial has two parts Part 1 involves healthy volunteers receiving a single intravenous dose of CPV-104 or placebo in a randomized, double-blind setting. Part 2 involves patients with C3G receiving four weekly intravenous doses of CPV-104 without placebo. Dose escalation depends on safety reviews. All treatments are given by healthcare professionals. Participants will be closely monitored through side-effect checks, blood and urine tests, ECGs, vital signs, and blood samples to measure drug levels and antibodies. For C3G patients, kidney function will also be observed. Safety Review Committee regularly reviews data to ensure participant safety. The study measures severe and serious adverse drug reactions up to 29 days for healthy volunteers and up to 50 days for C3G patients.

Age: 18Years +All GendersPhase 1
17 locations
P

Actively Recruiting

Researchers are evaluating the effectiveness and safety of the drug rilvegostomig compared with pembrolizumab as a first-line treatment for patients with metastatic non-small cell lung cancer mNSCLC whose tumors have high levels of PD-L1. This Phase III, randomized, double-blind, global study focuses on patients with mNSCLC who meet specific genetic and health criteria to understand how these treatments perform in this group. Participants receive either rilvegostomig or pembrolizumab, both given intravenously on the first day of each 21-day treatment cycle. The study has two groups one receiving rilvegostomig and the other pembrolizumab, with treatments continuing as part of their first-line cancer care. The trial monitors these treatments over several years to assess long-term outcomes. During the study, participants will have regular assessments including scans to measure tumor response, evaluations of physical function, quality of life questionnaires, and tests to monitor drug levels and immune responses. The main outcomes tracked are overall survival and progression-free survival over approximately five years. Safety and patient-reported symptoms are also closely monitored throughout the study period.

Age: 18Years +All GendersPhase 3
304 locations
L

Actively Recruiting

Researchers are evaluating the long-term safety and tolerability of dazodalibep in people with Sjgrens Syndrome. This phase 3 open-label study extends previous trials by continuing to monitor participants who completed 48 weeks of treatment with dazodalibep or placebo. The study is sponsored by Amgen and aims to better understand the safety profile of dazodalibep over an extended period. Participants who finished the initial 48-week trials HZNP-DAZ-301 or HZNP-DAZ-303 will receive an assigned dose of dazodalibep intravenously for an additional 132 weeks. This extension study involves a single treatment group receiving dazodalibep without placebo, focusing on ongoing treatment effects and participant safety. During the study, participants will be monitored for treatment-emergent adverse events for up to 152 weeks. Researchers will also measure the presence of anti-drug antibodies and plasma concentrations of dazodalibep for up to 132 weeks. Participants need to be available for all study visits and procedures, with safety assessments conducted regularly throughout the long-term extension period.

Age: 18Years +All GendersPhase 3
174 locations
L

Actively Recruiting

This research aims to evaluate the long-term effectiveness of mirikizumab in children and adolescents aged 2 to 19 years with moderate-to-severe ulcerative colitis or Crohns disease. The study is a phase 3, open-label, multicenter trial focusing on the treatment of these inflammatory bowel diseases and is sponsored by Eli Lilly and Company. It addresses the need for ongoing management of these chronic conditions in pediatric populations. Participants receive mirikizumab by subcutaneous injection in doses tailored to their weight across multiple administrations. In cases where response is lost, intravenous rescue dosing is available. This long-term extension study may include up to 44 visits over about 172 weeks. Additional treatment could be accessible through a Continued Access Period after the main study. During the study, participants are closely monitored through clinical assessments including remission and response evaluations using established scores like the Modified Mayo Score for ulcerative colitis and the Pediatric Crohns Disease Activity Index for Crohns disease. Researchers also examine endoscopic and histologic remission, corticosteroid use, and inflammation markers such as C-reactive protein. Safety and efficacy are tracked throughout, with participants undergoing regular visits for evaluations and treatment administration for nearly three and a half years.

Age: 2Years - 19YearsAll GendersPhase 3
69 locations
R

Actively Recruiting

Researchers are evaluating whether the drugs retatrutide and tirzepatide can prevent major adverse liver outcomes MALO in adults with metabolic dysfunction-associated steatotic liver disease MASLD, a condition that puts them at higher risk for severe liver problems. This Phase 3 trial is designed as a randomized, controlled study involving about 4,500 adults with MASLD identified through non-invasive tests indicating increased risk for liver complications. Participants will be randomly assigned to receive either retatrutide, tirzepatide, or a placebo, all given by subcutaneous injection. The study will last approximately 224 weeks, with up to 25 to 30 clinic visits to monitor health, conduct procedures, and assess liver function and disease progression. After completing the main study, eligible participants may join an optional 2-year extension where all receive either retatrutide or tirzepatide, regardless of initial assignment. Throughout the trial, participants will undergo assessments including liver fat content measurements, liver stiffness tests, liver fibrosis scores, and blood tests for liver enzymes and body weight changes. The primary outcome is the time until the first major adverse liver event occurs. Safety and disease progression will be closely monitored during and after treatment through regular clinic visits and evaluations.

Age: 18Years +All GendersPhase 3
563 locations
R

Actively Recruiting

Researchers are evaluating the effectiveness and safety of chemotherapy treatments in adults diagnosed with Blastic Plasmacytoid Dendritic Cell Neoplasm BPDCN. This observational study aims to provide comparative data to the ELZONRIS registry study by reviewing real-world outcomes of patients treated with various chemotherapy regimens as their first-line therapy since May 2016. Participants have received chemotherapy regimens similar to those used for acute myeloid leukemia, acute lymphocytic leukemia, or lymphoma, with choices made by their healthcare providers based on institutional practices. No study medication is provided by the sponsor. The study collects data retrospectively without administering new treatments. During the study, researchers collect information on response rates, duration of response, progression-free and overall survival, adverse events, transfusion needs, treatment durations, hospitalization details, and transitions to stem cell transplant. Data is gathered from the start of treatment through up to 26 months, offering insights into treatment patterns and outcomes. Participants privacy and consent are managed following local regulations.

Age: 18Years +All Genders
67 locations

1-10 of 333

1